Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023
Heidelberg Pharma AG will present new findings of its clinical Phase I/IIa study with the proprietary ADC candidate HDP-101 at the 65th Annual Meeting of the American Society of Hematology (ASH).
Dr. András Strassz, Chief Medical Officer at Heidelberg Pharma, commented: “We are very pleased with the progress of patient enrollment in our clinical trial with HDP-101. So far, HDP-101 has shown to be safe and well tolerated, and we will continue dose escalation in the fifth patient cohort (100 µg/kg) as planned.”